Investors reacted to lowered sales expectations from St. Jude Medical (NYSE:STJ) by sending shares down nearly 2% today on Wall Street.
2013
Baxter meets expectations with Q1 earnings report
Medical device sales down for Abbott during Q1
FLASH: St. Jude Medical’s Q1 profits rise despite 4% sales slide
St. Jude Medical (NYSE:STJ) posted increased profits during the 1st quarter despite reporting lower sales.
The St. Paul-based medical device company said profits for the 3 months ended March 30 were $223 million, or 78¢ per share, on sales of $1.34 billion. That’s a 5.2% bottom-line gain compared with Q1 2012, but a 4.1% top-line reduction.
Medical device earnings: Johnson & Johnson sees declines in several medtech divisions
Healthcare titan Johnson & Johnson (NYSE:JNJ) scored some hits and misses with Wall Street upon releasing its 1st-quarter 2013 earnings report, touting a 10% overall increase in medical devices and diagnostics revenues but failing to thrill analysts.
Biomet losses continue to expand amid growing sales
Orthopedic devices maker and market bellwether Biomet this week posted strong 3rd quarter revenue growth, with a boost in sales in the U.S. and abroad and a new trauma acquisition performing admirably, but losses continued to widen for the Warsaw, Ind.-based medical device company.
Medtech moods improving in 2013, survey says
Things are looking rosy in 2013 for the majority of respondents in a medical device industry survey, which aimed to capture attitudes about the year ahead.
Of the more than 3,000 survey participants, most said they were either "somewhat" or "very positive" about the general business environment the industry in 2013, and even more were optimistic about their own companies’ prospects for the year.
Medtronic cuts estimated medical device tax impact in half
Hospira lowers 2013 forecast after FDA bans more infusion pump imports
A “new era” for Boston Scientific?
Boston Scientific (NYSE:BSX) expects positive sales growth for the company by the 2nd half of 2013, CFO Jeffrey Capello told MassDevice.com in an interview.
A return to positive sales growth would end nearly 2.5 years of sliding revenues, and the medical device maker still has some rough patches to navigate, he said.
Medtronic narrows 2013 guidance
Medical device giant Medtronic(NYSE:MDT) narrowed its fiscal year 2013 guidance today, citing new clarity on the impact of the federal R&D tax credit.
The Minnesota device maker now expects earnings-per-share in the range of $3.66-$3.70 for fiscal year 2013, from previous guidance in the range of $3.62-$3.70, CEO Omar Ishrak told an audience at the J.P. Morgan Healthcare conference in San Francisco today.